Aurinia Pharmaceuticals (AUPH) Return on Invested Capital (2021 - 2025)
Aurinia Pharmaceuticals' Return on Invested Capital history spans 5 years, with the latest figure at 0.49% for Q4 2025.
- For Q4 2025, Return on Invested Capital rose 49.0% year-over-year to 0.49%; the TTM value through Dec 2025 reached 0.49%, up 49.0%, while the annual FY2025 figure was 0.48%, 49.0% up from the prior year.
- Return on Invested Capital reached 0.49% in Q4 2025 per AUPH's latest filing, up from 0.16% in the prior quarter.
- In the past five years, Return on Invested Capital ranged from a high of 0.49% in Q4 2025 to a low of 0.6% in Q3 2021.
- Average Return on Invested Capital over 5 years is 0.18%, with a median of 0.19% recorded in 2023.
- Peak YoY movement for Return on Invested Capital: increased 1bps in 2022, then soared 49bps in 2025.
- A 5-year view of Return on Invested Capital shows it stood at 0.47% in 2021, then surged by 41bps to 0.27% in 2022, then rose by 29bps to 0.2% in 2023, then soared by 96bps to 0.01% in 2024, then soared by 6259bps to 0.49% in 2025.
- Per Business Quant, the three most recent readings for AUPH's Return on Invested Capital are 0.49% (Q4 2025), 0.16% (Q3 2025), and 0.12% (Q2 2025).